Core Viewpoint - NeuroThera Labs Inc. has announced a collaboration with Clearmind Medicine Inc. to file a patent for an innovative combination therapy aimed at treating major depressive disorder (MDD) [1][3] Company Overview - NeuroThera Labs Inc. is a clinical-stage biotech company focused on developing novel therapeutics for central nervous system disorders through collaborations and innovative combinations [4] - Clearmind Medicine Inc. is a clinical-stage pharmaceutical biotech company dedicated to discovering and developing psychedelic-derived therapeutics for various health issues, including alcohol use disorder [5] Patent Filing and Therapy Details - Clearmind has filed a patent application in Hong Kong for a combination therapy that includes Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) sourced from NeuroThera [2][3] - The MEAI-PEA combination is positioned as a non-hallucinogenic neuroplastogen option for treating depression, which affects over 332 million people globally [3] Market Potential and Advantages - The anticipated mechanism of action for the MEAI-PEA therapy suggests it could offer a safer, more accessible, and affordable alternative to existing antidepressants, including SSRIs [3][8] - There is a growing demand for novel treatments for major depressive disorder, highlighting the potential market opportunity for this combination therapy [8]